Wordt geladen...
Phase II Study of the HDAC Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (CALGB 30304)
HYPOTHESIS: Treatment of small cell lung cancer (SCLC) is initially gratifying with most patients (pts) responding to platinum based chemotherapy. Treatment of relapsed disease gives much lower response rates of short duration. We undertook this study of the protein deacetylase inhibitor Romidepsin...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2010
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3782083/ https://ncbi.nlm.nih.gov/pubmed/20871263 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e3181ec1713 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|